Aminologics Co.Ltd Net Assets
Aminologics Co.Ltd net assets. Based on the latest financial reports, Aminologics Co.Ltd (074430) has net assets worth ₩58.43 Billion KRW (≈ $39.60 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩89.72 Billion ≈ $60.80 Million USD) and total liabilities (₩31.28 Billion ≈ $21.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Aminologics Co.Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩58.43 Billion |
| % of Total Assets | 65.13% |
| Annual Growth Rate | 0.39% |
| 5-Year Change | -5.72% |
| 10-Year Change | 25.69% |
| Growth Volatility | 28.98 |
Net Assets of Aminologics Co.Ltd (2008–2025)
Net assets of Aminologics Co.Ltd from 2008 to 2025. This chart illustrates how Aminologics Co.Ltd's net assets have evolved over time, based on quarterly financial data. See 074430 equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Aminologics Co.Ltd (2008–2025)
The table below shows the annual net assets of Aminologics Co.Ltd from 2008 to 2025. For live market cap and overall valuation, see 074430 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩55.99 Billion ≈ $37.95 Million |
+8.31% |
| 2024-12-31 | ₩51.70 Billion ≈ $35.03 Million |
-4.99% |
| 2023-12-31 | ₩54.41 Billion ≈ $36.87 Million |
+5.85% |
| 2022-12-31 | ₩51.40 Billion ≈ $34.84 Million |
-13.45% |
| 2021-12-31 | ₩59.39 Billion ≈ $40.25 Million |
+10.90% |
| 2020-12-31 | ₩53.56 Billion ≈ $36.30 Million |
+3.29% |
| 2019-12-31 | ₩51.85 Billion ≈ $35.14 Million |
-2.51% |
| 2018-12-31 | ₩53.19 Billion ≈ $36.04 Million |
+17.82% |
| 2017-12-31 | ₩45.14 Billion ≈ $30.59 Million |
+1.33% |
| 2016-12-31 | ₩44.55 Billion ≈ $30.19 Million |
-7.72% |
| 2015-12-31 | ₩48.28 Billion ≈ $32.72 Million |
+51.59% |
| 2014-12-31 | ₩31.85 Billion ≈ $21.58 Million |
-21.22% |
| 2013-12-31 | ₩40.42 Billion ≈ $27.39 Million |
+28.32% |
| 2012-12-31 | ₩31.50 Billion ≈ $21.35 Million |
-48.59% |
| 2011-12-31 | ₩61.27 Billion ≈ $41.52 Million |
+74.53% |
| 2010-12-31 | ₩35.11 Billion ≈ $23.79 Million |
-33.06% |
| 2008-12-31 | ₩52.44 Billion ≈ $35.54 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aminologics Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6977243084000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Aminologics Co.Ltd Net Assets Breakdown (December 2025)
Aminologics Co.Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩125.77 Billion | 224.61% |
| Total Equity | ₩55.99 Billion | 100.00% |
Aminologics Co.Ltd Competitors by Market Cap
The table below lists competitors of Aminologics Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kaulin Mfg
TW:1531
|
$64.26 Million |
|
Powerlogics Co. Ltd
KQ:047310
|
$64.26 Million |
|
Gagasan Nadi Cergas Berhad
KLSE:0206
|
$64.28 Million |
|
Aquila European Renewables Income PLC
LSE:AERI
|
$64.28 Million |
|
Kanpur Plastipack Limited
NSE:KANPRPLA
|
$64.25 Million |
|
Solutions 30 SE
F:30L3
|
$64.24 Million |
|
Jaiprakash Associates Limited
NSE:JPASSOCIAT
|
$64.24 Million |
|
Arn Media Ltd
AU:A1N
|
$64.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aminologics Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 51,695,321,420 to 55,993,501,590, a change of 4,298,180,170 (8.3%).
- Net income of 3,521,555,420 contributed positively to equity growth.
- Other factors increased equity by 776,624,750.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩3.52 Billion | +6.29% |
| Other Changes | ₩776.62 Million | +1.39% |
| Total Change | ₩- | 8.31% |
Book Value vs Market Value Analysis
This analysis compares Aminologics Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.58x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.99x to 1.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩507.22 | ₩1008.00 | x |
| 2017-12-31 | ₩513.99 | ₩1008.00 | x |
| 2018-12-31 | ₩605.60 | ₩1008.00 | x |
| 2019-12-31 | ₩590.39 | ₩1008.00 | x |
| 2020-12-31 | ₩609.81 | ₩1008.00 | x |
| 2021-12-31 | ₩676.25 | ₩1008.00 | x |
| 2022-12-31 | ₩585.29 | ₩1008.00 | x |
| 2023-12-31 | ₩619.53 | ₩1008.00 | x |
| 2024-12-31 | ₩588.61 | ₩1008.00 | x |
| 2025-12-31 | ₩637.54 | ₩1008.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aminologics Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.29%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.99%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.50x
- Recent ROE (6.29%) is above the historical average (-1.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -25.43% | -228.75% | 0.09x | 1.21x | ₩-11.28 Billion |
| 2015 | -5.85% | -25.69% | 0.20x | 1.14x | ₩-7.65 Billion |
| 2016 | -8.40% | -22.86% | 0.33x | 1.10x | ₩-8.20 Billion |
| 2017 | 1.20% | 3.22% | 0.34x | 1.09x | ₩-3.97 Billion |
| 2018 | 15.03% | 43.34% | 0.32x | 1.07x | ₩2.68 Billion |
| 2019 | -2.32% | -6.33% | 0.33x | 1.11x | ₩-6.39 Billion |
| 2020 | 4.00% | 12.12% | 0.29x | 1.12x | ₩-3.22 Billion |
| 2021 | 9.02% | 23.46% | 0.35x | 1.10x | ₩-579.48 Million |
| 2022 | -14.17% | -26.64% | 0.49x | 1.08x | ₩-12.42 Billion |
| 2023 | 4.48% | 11.66% | 0.36x | 1.06x | ₩-3.00 Billion |
| 2024 | -3.13% | -9.65% | 0.30x | 1.10x | ₩-6.79 Billion |
| 2025 | 6.29% | 15.99% | 0.26x | 1.50x | ₩-2.08 Billion |
Industry Comparison
This section compares Aminologics Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $101,034,626,727
- Average return on equity (ROE) among peers: 12.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aminologics Co.Ltd (074430) | ₩58.43 Billion | -25.43% | 0.54x | $64.25 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $266.11 Billion | -4.10% | 0.95x | $2.49 Billion |
| DongKoo Bio & Pharma Co. Ltd. (006620) | $2.55 Billion | 158.01% | 22.83x | $21.80 Million |
| NatureCell Co.Ltd (007390) | $13.75 Billion | 13.78% | 0.78x | $793.12 Million |
| Sam-A Pharm. Co. Ltd (009300) | $200.47 Billion | 10.66% | 0.15x | $56.13 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $259.82 Billion | 4.88% | 0.12x | $78.42 Million |
| WooGene B&G Co. Ltd (018620) | $27.27 Billion | -46.89% | 2.12x | $46.98 Million |
| Oscotec Inc (039200) | $21.78 Billion | -9.28% | 0.67x | $674.16 Million |
| EstechPharma Co. Ltd (041910) | $115.63 Billion | 3.31% | 0.05x | $42.90 Million |
| Komipharm International Co. Ltd (041960) | $60.02 Billion | -6.63% | 0.98x | $343.99 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $42.95 Billion | 6.15% | 0.28x | $25.96 Million |
About Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more